Sanofi (SNY) issued the following statement regarding Horizon Therapeutics plc (HZNP): "Sanofi S.A. regularly evaluates a wide variety of business development opportunities and this has included the evaluation of a possible transaction involving Horizon. As transaction price expectations do not meet our value creation criteria, Sanofi announces it is no longer in discussions with Horizon and it does not intend to make an offer for Horizon. This announcement is intended to be treated as a statement to which Rule 2.8 of the Takeover Rules applies."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Amgen (NASDAQ:AMGN) to Buy Horizon for $27.8B; HZNP Stock Rallies
- Horizon Therapeutics announces first subject does in HZN-457 trial
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler
- J&J says ‘it does not intent to make offer’ for Horizon Therapeutics
- J&J says won’t make offer for Horizon Therapeutics, Bloomberg reports